Digital Pharmaceutical Process Design: Faster, Cost Effective and Sustainable Delivery of Quality Drug Substance
Industry Engagement, Research, National Facility Steven Scott Industry Engagement, Research, National Facility Steven Scott

Digital Pharmaceutical Process Design: Faster, Cost Effective and Sustainable Delivery of Quality Drug Substance

CMAC’s digital‑first process design is cutting pharmaceutical development timelines and material use by an order of magnitude while delivering high‑quality drug substance. By replacing trial‑and‑error experimentation with predictive modelling, it enables faster, more cost‑effective and sustainable manufacturing.

Read More
From Lab to Clinical Development: CMAC’s Impurity Rejection Workflow
Industry Engagement, National Facility, Research Steven Scott Industry Engagement, National Facility, Research Steven Scott

From Lab to Clinical Development: CMAC’s Impurity Rejection Workflow

CMAC’s impurity rejection workflow provides industry with a systematic, material‑efficient approach to achieving high‑purity crystalline products in drug manufacturing. Successfully applied by Eli Lilly in clinical development, it enables robust control of impurity‑related CQAs and accelerates crystallisation process design.

Read More
Peptide Isolation via Spray Drying: Investigating Particle Formation and Means of Process Implementation
Skills, Research Steven Scott Skills, Research Steven Scott

Peptide Isolation via Spray Drying: Investigating Particle Formation and Means of Process Implementation

This collaborative CMAC–Eli Lilly project explores spray drying as a faster, scalable alternative to lyophilisation for isolating therapeutic peptides. Through targeted experimentation and advanced data capture, it delivers practical guidance for improving manufacturability and accelerating peptide drug development.

Read More